TxCELL appoints chief medical officer
TxCell, a French biotechnology company developing cell-based therapies using Type 1 T-regulatory lymphocytes for treating chronic inflammatory and autoimmune diseases, has appointed Miguel Forte to the newly created role of chief medical officer.
Forte will take charge of the clinical department, clinical operations, clinical trials management and design. He joins the company from UCB, where he was vice-president, Global Medical Affairs Inflammation Worldwide. Prior to this, he spent two years at Nabi Pharmaceuticals as vice-president, Clinical, Medical and Regulatory Affairs Europe.
You may also like
Research & Development
TxCell Signs inlicensing agreement with Inserm Transfert for novel population of regulatory T cells
TxCell SA, a biotechnology company developing innovative, personalised cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, and Inserm Transfert, on behalf of Inserm, the Nantes University (Nantes, France) and the Nantes CHU, have announced the signature of an exclusive worldwide licensing agreement
